Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine
·
23:19
|
In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:
Usona Institute files its psilocybin for major depressive disorder new drug application with FDA
FDA approves NRx Pharmaceuticals’ preservative-free generic ketamine
We share our analysis of 610 public comments on FDA’s psychedelics docket
ICER is set to review Compass Pathways’ psilocybin for treatment-resistant depression
More takeaways from The Psychedelic Healthcare Forum
The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.
This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.
Episode 4
